Clik here to view.
Genomic Leaders Collaborate to Create Australia’s First National COVID-19...
MELBOURNE, Australia Illumina (NASDAQ: ILMN) announced today that the Australian public health laboratories will aim to sequence the virus genomes of all positive COVID-19 tests in Australia and...
View ArticleClik here to view.
Octapharma宣布FDA批准NUWIQ®处方信息更新版，以纳入既往未曾治疗的患者的免疫原性数据
瑞士拉亨 (美国商业资讯)– Octapharma欣然宣布，美国食品药品管理局(FDA)已批准NUWIQ®处方信息(PI)的更新版，NUWIQ®是Octapharma的人细胞株系衍生重组第八因子(FVIII)。NUWIQ®获准用于预防和治疗血友病A患者的出血。更新版PI纳入NuProtect研究中既往未曾治疗的患者(PUP)的免疫原性数据。 重症血友病A既往未曾治疗的患者...
View ArticleClik here to view.
Dren Bioが6000万ドルのシリーズA資金調達を発表
米カリフォルニア州サンカルロス （ビジネスワイヤ） — 細胞、タンパク質凝集体、その他の疾患原因物質を枯渇させる強力なタンパク質工学技術を開発している企業のDren Bioは、6000万ドルのシリーズA投資ラウンドを終了したと発表しました。本ラウンドはSR...
View ArticleClik here to view.
オクタファルマ、NUWIQ®の添付文書に未治療患者での免疫原性のデータを含める更新をFDAが承認と発表
スイス・ラッヘン （ビジネスワイヤ） — オクタファルマは、米国食品医薬品局（FDA）が当社のヒト細胞株由来組み換え型第VIII因子（FVIII）製剤NUWIQ®に対する添付文書の更新を承認したと発表しました。NUWIQ...
View ArticleClik here to view.
CANbridge Pharmaceuticals Appoints Head of Global Research
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed...
View ArticleClik here to view.
CANbridge Pharmaceuticals Appoints Head of Global Research
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has appointed...
View ArticleClik here to view.
EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted...
View ArticleClik here to view.
EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc. ( “Company”, or “EdiGene”), today announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted...
View ArticleClik here to view.
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America...
View ArticleClik here to view.
Takeda Presents Rare Bleeding Disorders Research at Thrombosis & Hemostasis...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented four abstracts at the Thrombosis and Hemostasis Summit of North America...
View ArticleClik here to view.
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and...
OSAKA, Japan & DURHAM, N.C. Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive...
View ArticleClik here to view.
Modalis Therapeutics Reports Third Quarter 2020 Financial Results and...
TOKYO & CAMBRIDGE, Mass. Modalis Therapeutics Corporation (Modalis) (TOKYO: 4883), a leading company developing innovative products for the treatment of rare genetic diseases utilizing its...
View ArticleClik here to view.
SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host...
SYDNEY SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an...
View ArticleClik here to view.
SpeeDx与Nepean医院合作，实现呼吸道病毒宿主生物标记物检测的商业化
悉尼 (美国商业资讯)–SpeeDx Pty. Ltd.是创新分子诊断解决方案的开发者，已与Nepean蓝山地区卫生区(NBMLHD) Nepean医院的研究人员合作，达成一项排他性协议，将呼吸道病毒性疾病宿主基因表达生物标记物检测商业化。由NBMLHD的Anthony Maclean博士、Benjamin...
View ArticleClik here to view.
Realize the Full Potential of the NextSeq 2000 with the Power of the P3...
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell...
View ArticleClik here to view.
KILL Realize the Full Potential of the NextSeq 2000 with the Power of the P3...
Illumina, Inc. requests that their press release NewsItemId: 20201112005379 “Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit” be removed. CONTACT Business Wire,...
View ArticleClik here to view.
P3試薬キットのパワーでNextSeq 2000システムの潜在能力をフルに活用
サンディエゴ （ビジネスワイヤ） — Illumina, Inc. (NASDAQコード: ILMN) は、高データ出力のP3フローセルの販売により、NextSeq™...
View ArticleClik here to view.
D3 Bio Launches with US$200 Million Investment to Develop Precision Medicines...
SHANGHAI D3 Bio, a global biotechnology company focused on developing and commercializing precision medicines to improve or replace existing standard-of-care treatments that do not fully meet...
View ArticleClik here to view.
PierianDx and Bench International Announce the Appointment of Mark McDonough...
ST. LOUIS & SAN DIEGO PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark...
View ArticleClik here to view.
PierianDxとベンチ・インターナショナルがマーク・マクドナーを新たな最高経営責任者（CEO）に任命したと発表
セントルイス & サンディエゴ （ビジネスワイヤ） —...
View Article